DarioHealth (DRIO) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Speaker0 morning, ladies and gentlemen, and welcome to the DarioHealth First Quarter twenty twenty five Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Wednesday, 05/14/2025. I would now like to turn the conference over to Kat Paralla, Investor Relations Manager at Dario. Kat, please go ahead. Speaker1 Thank you, ...

First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially. Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024 Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024 Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through ongoing AI-driven process optimization GAA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37704 | DarioHealth Corp. | | | | --- | --- | --- | | (Exact name of registrant as specified in its charter) | | | | ...

New data, published in JMIR, demonstrates the value of personalized messaging encouraging flu vaccinations in Dario members with diabetes NEW YORK, May 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the Journal of Medical Internet Research ("JMIR") demonstrating the effectiveness of personalized digital health interventions to drive flu vaccine awareness in Dario members living with ...

NEW YORK, May 7, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 14th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Wedne ...

NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company un ...

Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025 NEW YORK, April 17, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new strategic partnership with a leading benefit administrator to deliver its comprehensive cardiometabolic solution including a GLP-1 support program and full AI-driven digital health suite to employers, with initia ...

Second major healthcare employer signs with DarioHealth, accelerating growth in 2025 and reinforcing its leadership in AI-powered, clinically validated digital health solutions for chronic condition managementNEW YORK, April 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new employer partnership with one of the nation's most respected research and medical institutions. The signed agreement is already live a ...

文章核心观点 - 达里奥健康公司（DarioHealth Corp.）被升级为Zacks排名第一（强力买入），反映了盈利预期上升趋势，可能对股价产生积极影响 [1][3] 评级系统介绍 - Zacks评级唯一决定因素是公司盈利情况变化，系统跟踪当前和下一年度的Zacks共识预期 [2] - Zacks评级系统对个人投资者很有用，因其基于盈利预期变化判断短期股价走势，而华尔街分析师评级多受主观因素影响 [3] - Zacks排名股票评级系统用四个与盈利预期相关因素将股票分为五组，从强力买入到强力卖出，自1988年以来，Zacks排名第一的股票平均年回报率为+25% [7] 盈利预期与股价关系 - 公司未来盈利潜力变化与短期股价走势强相关，机构投资者用盈利和盈利预期计算股票公允价值，其大量交易导致股价变动 [4] - 达里奥健康公司盈利预期上升和评级上调意味着公司基本面业务改善，投资者应推动股价上涨 [5] - 盈利预期修正趋势与短期股票走势强相关，跟踪此类修正进行投资决策可能有回报，Zacks排名系统有效利用了这一力量 [6] 达里奥健康公司盈利预期情况 - 截至2025年12月的财年，公司预计每股收益为 -$0.22，较上年报告数字变化 -83.3% [8] - 过去三个月，公司的Zacks共识预期增长了58.5% [8] 评级结论 - Zacks评级系统对超4000只股票保持“买入”和“卖出”评级的均衡比例，只有前5%的股票获“强力买入”评级，前20%的股票盈利预期修正表现优越，有望近期跑赢市场 [9][10] - 达里奥健康公司升级为Zacks排名第一，处于Zacks覆盖股票的前5%，意味着股价近期可能上涨 [10]

文章核心观点 - 达里奥健康公司与蓝十字蓝盾达成新协议，扩大支付方网络，推动经常性收入增长，巩固其在医疗保健快速增长领域的地位，其人工智能驱动的数字健康平台受支付方青睐 [1] 公司动态 - 公司与蓝十字蓝盾健康计划达成新协议，该项目于2025年1月推出，会员可无缝使用公司基于证据、人工智能驱动的健康指导和监测工具 [1] - 协议将公司平台的心血管代谢数字健康综合解决方案整合到健康计划为雇主提供的会员服务套件中，已为2025年第一季度的年度经常性收入做出贡献，且与该健康计划的合作关系预计全年将进一步扩大 [2] - 此次合作强化了公司在全国提供数字心血管代谢护理解决方案的作用，目前公司服务九家健康计划，涵盖地区和全国支付方 [3] 公司高管观点 - 首席商务官史蒂文·尼尔森认为，此次扩张凸显支付方对可扩展、人工智能驱动的数字健康解决方案的需求增加，与蓝十字蓝盾的合作进一步验证公司在心血管代谢护理领域的市场领导地位，增强扩大经常性收入增长的能力，随着九家健康计划采用公司技术，公司正迅速扩大在数十亿美元支付方市场的影响力，朝着盈利和长期增长迈进 [4] 公司简介 - 达里奥健康公司是领先的数字健康公司，通过以用户为中心、多慢性病数字疗法平台，革新慢性病患者管理健康的方式，其平台和解决方案套件为糖尿病、高血压、体重管理、肌肉骨骼疼痛和行为健康提供由数据分析和一对一指导驱动的个性化动态干预措施 [5] - 公司以用户为中心的平台为人们提供持续定制的健康护理，打破传统医疗的阶段性模式，使人们能够全面调整生活方式，实现可持续的行为改变，带来出色的用户满意度、留存率和效果 [6] - 公司在全球向健康计划和其他支付方、自保雇主、护理提供者和消费者提供高用户评价的解决方案 [7] 行业规模 - 心血管代谢疾病市场预计到2033年将超过1.2万亿美元 [3]